These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15927843)

  • 1. New cytotoxic agents: a review of the literature.
    Hotta K; Ueoka H
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):45-65. PubMed ID: 15927843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic determinants of the activity and toxicity of antitumour agents.
    Newell DR
    Cancer Surv; 1989; 8(3):557-603. PubMed ID: 2701085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design.
    Pirvulescu C; von Minckwitz G; Loibl S
    Breast Care (Basel); 2008; 3(5):333-339. PubMed ID: 20824028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs in clinical development in the United States.
    Eckardt JR; Von Hoff DD
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):305-32. PubMed ID: 8040143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational agents for epithelial ovarian cancer.
    Muggia F; Kosloff R
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy for metastatic colorectal cancer].
    Iwasa S; Shimada Y
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1467-74. PubMed ID: 18799899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and antitumor activity of novel 20s-camptothecin analogues.
    Li Q; Lv H; Zu Y; Qu Z; Yao L; Su L; Liu C; Wang L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):513-5. PubMed ID: 19056266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New molecular targets and novel agents in the treatment of advanced urothelial cancer.
    Beekman KW; Bradley D; Hussain M
    Semin Oncol; 2007 Apr; 34(2):154-64. PubMed ID: 17382799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
    Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
    Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting novel and established therapies for non-small cell lung cancer.
    Spicer J; Chowdhury S; Harper P
    Cancer Lett; 2007 May; 250(1):9-16. PubMed ID: 17030089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on tubulin-binding agents.
    Attard G; Greystoke A; Kaye S; De Bono J
    Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in chemotherapy against advanced or metastatic colorectal cancer.
    Omura K
    Digestion; 2008; 77 Suppl 1():13-22. PubMed ID: 18204257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.
    Hamberg P; Verweij J; Seynaeve C
    Eur J Cancer; 2007 Jul; 43(10):1514-28. PubMed ID: 17482454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
    Burris HA
    Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in chemotherapy for advanced non-small cell lung cancer.
    Raez LE; Lilenbaum R
    Curr Opin Oncol; 2006 Mar; 18(2):156-61. PubMed ID: 16462185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.